Linkage to Care for Persons with Hep C Infection

NCT ID: NCT05397067

Last Updated: 2025-03-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-07-12
• Study Completion Date: 2025-02-04

Brief Summary

Hepatitis C Virus (HCV) infection is an ongoing challenge in the United States, with an estimated 2.4 million individuals living with HCV in 2016. According to the Virginia Department of Health, over 11,500 people were living with HCV infection in 2017 with a rate of 170 reported cases/100,000 adults. This same year, the situation was even more dire in Roanoke City which had a rate of 524/100,000 adults. Treatment with antiviral medication is curative and well tolerated. However, gaps remain in the ability of the health system to engage the most vulnerable patients to start and complete treatment. People with HCV infection usually are unaware of the infection, which allows the disease to progress to liver damage, liver cancer and death if left untreated.At each stage of the screening, testing, and treatment process, there is significant patient loss to follow-up. Drop-off most commonly occurs between diagnosis and the first visit to a treating provider.

Key barriers to successful engagement include: 1) communication issues, such as lack of phone or limited phone access; 2) lack of transportation; 3) significant social issues such as poverty; 4) substance use disorder; and 5) a limited understanding of the consequences of untreated HCV infection. In this mixed-method design, the investigators propose a pilot study that will provide education and resources, such as vouchers for phone, transportation, and meals, to the most vulnerable patients that will facilitate engagement in treatment as additional factors that may influence dropout rates are evaluated.

Detailed Description

Aim 1: To identify perceived barriers and facilitating factors to completion of HCV treatment by patients and providers at a local level.

The investigators will conduct a qualitative study, informed by current literature, asking patients with a new diagnosis of HCV infection, patients with a history of HCV infection, and providers who specialize in HCV treatment about their perceptions of barriers and facilitators to treatment.

Aim 2: To pilot simple solutions to known basic social problems affecting communication and access to HCV infection care, leveraging peer counselors who are trained in engaging and retaining patients with HCV infection in treatment by bringing earlier, language-appropriate education to patients, while facilitating the LTC process. The investigators will provide time for a Peer Specialist (PS) and vouchers (e.g., for phones, meals, and transportation) to patients at the point of their initial test. The investigators will specifically target people with substance use disorder (PWSD) as our population for this study.

Aim 3: To identify other system-based interventions to address those barriers and optimize the things that will facilitate care and LTC.

The investigators will conduct a local "call-to-action" to leverage local data on the incidence, prevalence, morbidity, and mortality associated with HCV infection, and the findings of our qualitative analysis from specific Aim 1, to identify actionable, sustainable interventions to increase adherence to HCV infection screening, testing, and treatment through systems improvement.

This project seeks to determine whether the interventions (PS, vouchers) influence individual attendance at the first treatment appointment. In addition, what additional factors might be influencing individuals to adhere to their first appointment. Do these individuals find the interventions useful? What other barriers exist?

The investigators will use a mixed methods approach to address these questions. A mixed methods approach was chosen because the quantitative data will allow the investigators to perform descriptive and inferential statistics. The qualitative data will add a richness to our understanding of why our interventions may or may not prove successful.

Qualitative study: This study will help the investigators to understand the extent to which interventions are adopted and what barriers to adoption might exist. The investigators plan to conduct semi-structured key informant interviews with 10 patients and 10 care providers. Interviews will last approximately 30 minutes. Barriers and facilitators (or perceived barriers and facilitators for care providers) to attendance at the first treatment appointment, will be discussed. It is anticipated to use the social-ecological model as a framework and will use axial coding for analysis. The output of this aim is anticipated to be a list of barriers and facilitators (Aim 1). The output of this aim will help to frame additional intervention studies in the future (Aim 3).

Quantitative study: Two types of intervention will be tested. The first is the provision of a PS, and the second is the use of vouchers (food, transportation, phone) to facilitate LTC. These two interventions are linked in this study (see limitations section). Our hypothesis is that this intervention will lead to a greater likelihood of the individual attending their first treatment appointment. Individuals that have a new diagnosis of HCV infection from the Carilion Clinic system will be provided a PS and specific vouchers based on the specialist's assessment of their specific needs at the time of their initial diagnosis. PS's work from the perspective of their lived experience with mental illness/substance use disorder and recovery. Being a PS requires being open about having been diagnosed with a mental illness or substance use disorder. This openness is to help educate others about the reality and the possibility of recovery. The investigators plan to work with them to help patients with substance use disorders and HCV infection to engage in the benefits of HCV treatment as well as to facilitate LTC.

The investigators will use a pragmatic trial (quasi-experimental) approach; specifically, an interrupted time-series design (3 phases) and analysis. The investigators will compare a sample of individuals newly diagnosed with HCV infection pre-implementation to a post-implementation sample, with a short washout period in the middle (phase 1-pre; phase 2-washout; phase 3-post). This is a between-subjects design. Our main measure of interest is attendance at the initial treatment appointment. Although an accurate power calculation is difficult, it is estimated that for an effect size of 2, an n of 36 per phase (36 pre and 36 post), should allow for detection of a 0.05 significant difference between pre- and post-implementation.19 This calculation is based on an assumption of no auto-correlation. The investigators anticipate using an ANOVA for statistical comparisons. The output of this analysis will be a preliminary test of the relationship of our intervention and attendance at the first treatment appointment. Since this is a pilot proposal, designed to build collaboration and ensure our processes are reliable, the investigators will also gather qualitative data on the process of giving out vouchers, the availability and use of the PS, and any other process variables of interest (Aim 3).

Conditions

Hepatitis C, Chronic; Substance Use Disorders

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: NONE

Study Groups

Peer specialist and Vouchers

Intervention arm

Group Type: EXPERIMENTAL

Peer specialist (PS) and vouchers

Intervention Type: BEHAVIORAL

this participants will receive vouchers from PS

Standard of care

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Peer specialist (PS) and vouchers

this participants will receive vouchers from PS

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

• 18 years or older, positive Hepatitis C antibody test,
• elevated Hepatitis C RNA
• history of substance use disorder

Exclusion Criteria

• under 18 years old,
• history of treatment of Hepatitis C infection

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Virginia Polytechnic Institute and State University

OTHER

Sponsor Role: collaborator

National Center for Advancing Translational Sciences (NCATS)

NIH

Sponsor Role: collaborator

Carilion Clinic

OTHER

Sponsor Role: lead

Responsible Party

Mariana Gomez

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Carilion Clinic

Roanoke, Virginia, United States

Countries

United States

Other Identifiers

UL1TR003015

Identifier Type: NIH

Identifier Source: secondary_id

View Link

IRB-21-1472

Identifier Type: -

Identifier Source: org_study_id